Worsening of Huntington disease phenotype in CB1 receptor knockout mice

Neurobiology of Disease

Volumn 42, Issue 3, 2011, Pages 524-529

  Mievis, Stéphane ^a   Blum, David ^b,c,d   Ledent, Catherine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

3 nitropropionic acid; CB1 receptor; Huntington's disease; N171 82Q; Striatum; Transgenic model

Indexed keywords

CANNABINOID 1 RECEPTOR; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; GENE DELETION; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL;

EID: 79954631581     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.03.006     Document Type: Article

References (44)

1. Bantubungi K., Blum D. Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features. Rev. Méd. Brux. 2007, 28:413-421.
2. Bantubungi K., Blum D. Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges. Rev. Méd. Brux. 2007, 28:487-494.
3. Bantubungi K., Jacquard C., Greco A., Pintor A., Chtarto A., Tai K., et al. Minocycline in phenotypic models of Huntington's disease. Neurobiol. Dis. 2005, 18:206-217.
4. Blázquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011, 134:119-136.
5. Blum D., Galas M.C., Gall D., Cuvelier L., Schiffmann S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 2002, 10:410-426.
6. Blum D., Galas M.C., Pintor A., Brouillet E., Ledent C., Muller C.E., et al. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 2003, 23:5361-5369.
7. Blum D., Gall D., Galas M.C., d'Alcantara P., Bantubungi K., Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 2002, 22:9122-9133.
8. Borrell-Pagès M., Canals J.M., Cordelières F.P., Parker J.A., Pineda J.R., Grange G., et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 2006, 116(5):1410-1424.
9. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427-468.
10. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Conde F., Palfi S., et al. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 1998, 70:794-805.
11. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 2005, 95:1521-1540.
12. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martin-Ibanez R., Munoz M.T., et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004, 24:7727-7739.
13. Denovan-Wright E.M., Robertson H.A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 2000, 98:705-713.
14. Dowie M.J., Bradshaw H.B., Howard M.L., Nicholson L.F., Faull R.L., Hannan A.J., et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 2009, 163:456-465.
15. Dowie M.J., Howard M.L., Nicholson L.F., Faull R.L., Hannan A.J., Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience 2010, 170:324-336.
16. Duan W., Peng Q., Masuda N., Ford E., Tryggestad E., Ladenheim B., et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 2008, 30:312-322.
17. Fan M.M., Raymond L.A. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
18. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009, 156:1029-1040.
19. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
20. Glass M., van Dellen A., Blakemore C., Hannan A.J., Faull R.L. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 2004, 123:207-212.
21. Kofalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.S., Cunha R.A., et al. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J. Neurosci. 2005, 25:2874-2884.
22. Lastres-Becker I., Berrendero F., Lucas J.J., Martin-Aparicio E., Yamamoto A., Ramos J.A., et al. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. 2002, 929:236-242.
23. Lastres-Becker I., Bizat N., Boyer F., Hantraye P., Brouillet E., Fernandez-Ruiz J. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 2003, 14:813-816.
24. Lastres-Becker I., Bizat N., Boyer F., Hantraye P., Fernandez-Ruiz J., Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 2004, 15:2375-2379.
25. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
26. Maccarrone M., Battista N., Centonze D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog. Neurobiol. 2007, 81:349-379.
27. Mailleux P., Vanderhaeghen J.J. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci. Lett. 1992, 148:173-176.
28. Masuda N., Peng Q., Li Q., Jiang M., Liang Y., Wang X., et al. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol. Dis. 2008, 30:293-302.
29. Mievis S., Blum D., Ledent C. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2011, 41:570-576.
30. Mievis S., Levivier M., Communi D., Vassart G., Brotchi J., Ledent C., et al. Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromolecular Med. 2007, 9:47-54.
31. Naver B., Stub C., Moller M., Fenger K., Hansen A.K., Hasholt L., et al. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122:1049-1057.
32. Pantel J., Legendre M., Cabrol S., Hilal L., Hajaji Y., Morisset S., et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 2006, 116:760-768.
33. Pintor A., Tebano M.T., Martire A., Grieco R., Galluzzo M., Scattoni M.L., et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006, 51:1004-1012.
34. Roze E., Saudou F., Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr. Opin. Neurol. 2008, 21:497-503.
35. Sagredo O., Ramos J.A., Decio A., Mechoulam R., Fernandez-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 2007, 26:843-851.
36. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
37. Scotter E.L., Goodfellow C.E., Graham E.S., Dragunow M., Glass M. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br. J. Pharmacol. 2010, 160:747-761.
38. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn. Schmiedebergs. Arch. Pharmacol. 2002, 366:381-416.
39. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
40. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci. 2007, 27:3663-3676.
41. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
42. Walker F.O. Huntington's Disease. Semin. Neurol. 2007, 27:143-150.
43. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81:294-330.
44. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.